CIP
PRCT icon

Champlain Investment Partners’s Procept Biorobotics PRCT Stock Holding History

Champlain Investment Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.4M Sell
1,136,322
-304,712
-21% -$8.59M 0.36% 95
2025
Q4 		$45.3M Buy
1,441,034
+3,137
+0.2% +$104K 0.46% 87
2025
Q3 		$51.3M Buy
1,437,897
+367,251
+34% +$16.8M 0.39% 102
2025
Q2 		$61.7M Buy
1,070,646
+394,450
+58% +$22.3M 0.43% 96
2025
Q1 		$39.4M Buy
676,196
+219,266
+48% +$15M 0.29% 122
2024
Q4 		$36.8M Sell
456,930
-193,363
-30% -$16.5M 0.23% 121
2024
Q3 		$52.1M Sell
650,293
-714,986
-52% -$50.8M 0.31% 104
2024
Q2 		$83.4M Sell
1,365,279
-207,030
-13% -$12.3M 0.51% 82
2024
Q1 		$77.7M Sell
1,572,309
-15,730
-1% -$749K 0.44% 89
2023
Q4 		$66.6M Buy
1,588,039
+19,645
+1% +$669K 0.39% 93
2023
Q3 		$51.5M Buy
+1,568,394
New +$53.5M 0.33% 103

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Champlain Investment Partners's PRCT Position: Q1 2026 in Review

Champlain Investment Partners reduced its Procept Biorobotics (PRCT) stake by 21% in Q1 2026, selling an estimated $8.59M and leaving 1,136,322 shares worth $28.4M. The position accounts for 0.36% of the portfolio, ranked #95.

Champlain Investment Partners first reported a position in PRCT in Q3 2023 and has held it in 11 quarters since. The position peaked at $83.4M in Q2 2024. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Champlain Investment Partners held 1,136,322 shares of Procept Biorobotics worth $28.4M as of Q1 2026.
  • Champlain Investment Partners sold 304,712 Procept Biorobotics shares in Q1 2026, an estimated $8.59M.
  • Procept Biorobotics made up 0.36% of Champlain Investment Partners's portfolio in Q1 2026, its #95 holding.
  • Champlain Investment Partners first reported a position in Procept Biorobotics in Q3 2023 and has held it in 11 quarters since.
  • Champlain Investment Partners's Procept Biorobotics position peaked at $83.4M in Q2 2024.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Champlain Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.